Optimizing systemic therapy for bladder cancer

Area of Science:

• Oncology
• Urology

Background:

• Limited new systemic agents for bladder cancer treatment over decades.
• Platinum-based therapy is the standard but underutilized in the neoadjuvant setting.
• Second-line metastatic treatment shows modest activity without survival benefit.

Purpose of the Study:

• To review evidence supporting current bladder cancer treatment recommendations.
• To detail ongoing targeted therapy studies for bladder cancer.
• To highlight the need for continued education on optimal treatment use.

Main Methods:

• Review of evidence from prospective studies and meta-analyses.
• Analysis of NCCN guidelines basis.
• Summary of past and current targeted therapy investigations.

Main Results:

• Cisplatin-based therapy use in the neoadjuvant setting is low despite evidence.
• Limited efficacy and no survival benefit observed in second-line metastatic treatment.
• Active investigation into novel molecular targets and therapeutics is changing the treatment landscape.

Conclusions:

• Despite rapid advancements, no new drugs are currently pending approval.
• Optimal use of existing treatments requires ongoing education for medical oncology and urology professionals.
• Targeted therapies and biomarker research hold promise for future bladder cancer treatment strategies.